Skip to main navigation

> Main Menu

About Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency

Careers

Contact

Investors Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

> Main Menu

About

Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency

Careers Contact

Investors

Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

Press Releases

Year

September 26, 2023

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

August 9, 2023

Harrow Announces Second Quarter 2023 Financial Results

July 31, 2023

Harrow Launches VIGAMOX® in the U.S.

July 26, 2023

Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023

July 19, 2023

Harrow Prices $60 Million Public Offering of Common Stock

July 18, 2023

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

July 18, 2023

Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance

July 18, 2023

Harrow Announces Proposed Public Offering of Common Stock

July 18, 2023

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

May 17, 2023

Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 23

Address

102 Woodmont Blvd., Suite 610
Nashville, TN 37205

Phone

(615) 733 4730
(615) 733 4737 (Investor Relations)

Social

© 2023 Harrow Health, Inc.

> Footer

Privacy Policy Cookie Notice